Albert Santamaria-Martínez

May 28, 2024 | nature.com | Aaron S. Petruzzella |Marine Bruand |Albert Santamaria-Martínez |Natalya Katanayeva |Luc Reymond |Sandrine Georgeon | +6 more

AbstractCysteine cathepsins are a family of proteases that are relevant therapeutic targets for the treatment of different cancers and other diseases. However, no clinically approved drugs for these proteins exist, as their systemic inhibition can induce deleterious side effects. To address this problem, we developed a modular antibody-based platform for targeted drug delivery by conjugating non-natural peptide inhibitors (NNPIs) to antibodies.